FDA records indicate that there are no current recalls for this drug.
Are you a medical professional?
Trending Topics
Cough Control Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Warnings
- Stop use and ask your doctor if symptoms persist or worsen.
- If pregnant or breast-feeding, take only on advice of a healthcare professional.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Uses for temporary relief of cough symptoms: dry or hoarse cough, hacking, barking, tickling or spasmodic cough, croupy cough, throat irritation, excess mucus. Note: If cough persists for more than one week, consult a doctor.
History
There is currently no drug history available for this drug.
Other Information
There are no additional details available for this product.
Sources
Cough Control Manufacturers
- King Bio Inc.
- L&r Distributors, Inc.
- Stephen L. Lafrance Pharmacy, Inc.
Cough Control | Mylan Institutional Inc.
Rifampin can be administered by the oral route (see INDICATIONS AND USAGE). See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure.
TuberculosisAdults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, orally.
Pediatric Patients: 10 to 20 mg/kg, not to exceed 600 mg/day, orally.
It is recommended that oral rifampin capsule be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.
Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER® (Sanofi-aventis U.S. LLC)) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.
Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE® (Sanofi-aventis U.S. LLC)) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.
Meningococcal CarriersAdults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.
Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.
Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.
Preparation of Extemporaneous Oral SuspensionFor pediatric and adult patients in whom capsule swallowing is difficult or where lower doses are needed, a liquid suspension may be prepared as follows:
Rifampin 1% w/v suspension (10 mg/mL) can be compounded using one of four syrups-Simple Syrup (Syrup NF), Simple Syrup (Humco Laboratories), Syrpalta® Syrup (Emerson Laboratories) or Raspberry Syrup (Humco Laboratories).
• Empty the contents of four Rifampin 300 mg capsules or eight Rifampin 150 mg capsules onto a piece of weighing paper. • If necessary, gently crush the capsule contents with a spatula to produce a fine powder. • Transfer the rifampin powder blend to a 4-ounce amber glass or plastic (high density polyethylene [HDPE], polypropylene, or polycarbonate) prescription bottle. • Rinse the paper and spatula with 20 mL of one of the above mentioned syrups, and add the rinse to the bottle. Shake vigorously. • Add 100 mL of syrup to the bottle and shake vigorously.This compounding procedure results in a 1% w/v suspension containing 10 mg rifampin/mL. Stability studies indicate that the suspension is stable when stored at room temperature (25 ± 3° C) or in a refrigerator (2 to 8° C) for four weeks. This extemporaneously prepared suspension must be shaken well prior to administration.
- L&r Distributors, Inc.
Login To Your Free Account